CD20 in other B-cell lymphoma

1 EU-approved indication in other B-cell lymphoma needs a CD20 result: rituximab (1st line, advanced).
Approved indications, Other B-cell lymphoma
DrugBiomarker requirementRegimenSettingConditions
CD20-positive1
Rituximab
MabThera
+ chemotherapy
1L
advanced
Children and adolescents only; Aged 6 months to less than 18 years old

See also

Label wording1

The sentence from section 4.1 of the SmPC that each indication above comes from.

  1. Rituximab (MabThera)
    MabThera in combination with chemotherapy is indicated for the treatment of paediatric patients (aged 6 months to less than 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL).